Senseonics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:27 pm EST
Share
Senseonics Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 6.1 million compared to USD 4.62 million a year ago. Revenue was USD 6.1 million compared to USD 4.62 million a year ago. Net loss was USD 24.1 million compared to USD 60.39 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.13 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.13 a year ago.
For the nine months, sales was USD 14.36 million compared to USD 10.82 million a year ago. Revenue was USD 14.36 million compared to USD 10.82 million a year ago. Net loss was USD 43.2 million compared to net income of USD 130.56 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to basic earnings per share from continuing operations of USD 0.28 a year ago. Diluted loss per share from continuing operations was USD 0.08 compared to USD 0.1 a year ago.
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.